| 前收盘价格 | 18.42 |
| 收盘价格 | 18.51 |
| 成交量 | 784,657 |
| 平均成交量 (3个月) | 1,515,906 |
| 市值 | 1,680,132,352 |
| 价格/销量 (P/S) | 150.97 |
| 股市价格/股市净资产 (P/B) | 6.40 |
| 52周波幅 | |
| 利润日期 | 6 Nov 2025 |
| 营业利益率 (TTM) | -1,525.50% |
| 稀释每股收益 (EPS TTM) | -3.01 |
| 季度收入增长率 (YOY) | 184.40% |
| 总债务/股东权益 (D/E MRQ) | 1.55% |
| 流动比率 (MRQ) | 10.49 |
| 营业现金流 (OCF TTM) | -152.68 M |
| 杠杆自由现金流 (LFCF TTM) | -117.16 M |
| 资产报酬率 (ROA TTM) | -33.54% |
| 股东权益报酬率 (ROE TTM) | -69.21% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Immunome, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.8
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.75 |
|
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 11.48% |
| 机构持股比例 | 83.28% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| T. Rowe Price Investment Management, Inc. | 30 Sep 2025 | 8,418,163 |
| Redmile Group, Llc | 30 Sep 2025 | 5,023,385 |
| Point72 Asset Management, L.P. | 30 Sep 2025 | 4,824,504 |
| Enavate Sciences Gp, Llc | 30 Sep 2025 | 4,768,583 |
| Ecor1 Capital, Llc | 30 Sep 2025 | 4,079,415 |
| Price T Rowe Associates Inc /Md/ | 30 Sep 2025 | 3,742,770 |
| Opaleye Management Inc. | 30 Sep 2025 | 3,185,000 |
| Primecap Management Co/Ca/ | 30 Sep 2025 | 3,018,009 |
| Jefferies Financial Group Inc. | 30 Sep 2025 | 2,100,000 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 36.00 (Truist Securities, 96.51%) | 购买 |
| 中 | 29.50 (61.03%) | |
| 低 | 26.00 (Goldman Sachs, 41.92%) | 购买 |
| 26.00 (Craig-Hallum, 41.92%) | 购买 | |
| 平均值 | 30.25 (65.12%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 14.19 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Truist Securities | 01 Dec 2025 | 36.00 (96.51%) | 购买 | 18.32 |
| Stephens & Co. | 17 Nov 2025 | 33.00 (80.13%) | 购买 | 18.13 |
| Goldman Sachs | 22 Sep 2025 | 26.00 (41.92%) | 购买 | 9.77 |
| Craig-Hallum | 05 Sep 2025 | 26.00 (41.92%) | 购买 | 10.52 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合